3 completed, 2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Lymphangioma, Cystic: new trials by email Literature Review of Lymphangioma, Cystic trials Research Report on Lymphangioma, Cystic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiological Diagnosis of Pediatric Neck Swellings Lipoma, Branchial Cleft Anomalies | Active not recruiting | Sohag University | 50 | 2026-02-20 | 2026-07-30 | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| Bleomycin Intralesional Injections of Cystic Hygromas Intralesional Injections - Lymphatic Malformations | Not applicable | Completed | Delta University for Science and Technology | 30 | 2024-09-01 | 2026-04-28 |
| Ultraspound-guided Intralesional Injection of Cystic Hygroma - A Case Report Intralesional Injection of Bleomycin - Intralesional Injection of Cystic Hygroma, Cystic Hygroma (Macro-cystic Lymphatic Malformation) | Not applicable | Completed | Delta University for Science and Technology | 1 | 2024-09-01 | 2026-04-30 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Alpelisib, Placebo - Lymphatic Malformations | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 232 | 2023-11-24 | 2026-10-09 |
| Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations picibanil - Lymphatic Malformations | Phase 2 / Phase 3 | Completed | University of Iowa | 150 | 2000-04-01 | 2015-03-25 |
Lymphatic Abnormalities (4) · Lymphangioma (3) · Arteriovenous Malformations (1) · Branchial Cleft Anomalies (1) · Branchioma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Hemangioma (1) · Lipoma (1) · Lymphadenitis (1) · Rhabdomyosarcoma (1) · Skin Diseases, Vascular (1) · Thyroglossal Cyst (1) · Vascular Malformations (1)
Neoplasm, Lymphatic Tissue (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Hemic and Lymphatic Diseases (5) · Lymphatic Diseases (5) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Lymphangioma (3) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Cysts (1) · Myosarcoma (1) · Neoplasms, Adipose Tissue (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Muscle Tissue (1)
Alpelisib (2) · Injections, Intralesional (1) · Picibanil (1) · mirdametinib (1)
Delta University for Science and Technology (2) · Murdoch Childrens Research Institute (1) · Novartis Pharmaceuticals (1) · Sohag University (1) · University of Iowa (1)
Egypt (3) · Australia (2) · United States (2) · Argentina (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Gamal El-Tagy, MD (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Mohamad Zaki Ali, MD (1) · Richard J Smith (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1)
2023 (1)